フマリルアセトアセターゼ
“Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I)”. Am. J. Hum. Genet. 47 (2): 308–16. PMC 1683717. PMID 2378356. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1683717/.
Laberge C, Grenier A, Valet JP, Morissette J (1990). “Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I”. Am. J. Hum. Genet. 47 (2): 325–8. PMC 1683713. PMID 2378358. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1683713/.
Kvittingen EA, Halvorsen S, Jellum E (1983). “Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia”. Pediatr. Res. 17 (7): 541–4.